Akebia Therapeutics Inc. buy BTIG Research
Start price
29.10.25
/
50%
€1.93
Target price
29.10.26
€4.29
Performance (%)
-39.89%
Price
20.01.26
€1.12
Summary
This prediction is currently active. The BUY prediction by BTIG_Research for Akebia Therapeutics Inc. is performing very badly with a performance of -39.89%. This prediction currently runs until 29.10.26. The prediction end date can be changed by BTIG_Research at any time. BTIG_Research has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Akebia Therapeutics Inc. | -4.831% | -4.831% |
| iShares Core DAX® | -3.141% | 1.269% |
| iShares Nasdaq 100 | -3.518% | -1.355% |
| iShares Nikkei 225® | -3.396% | 3.283% |
| iShares S&P 500 | -2.943% | -0.533% |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at BTIG Research from $10.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Stopped prediction by BTIG_Research for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.27
02.12.25
02.12.25
€4.31
02.12.26
02.12.26
-9.03%
20.01.26
20.01.26
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.92
29.11.23
29.11.23
€3.64
29.11.24
29.11.24
122.78%
30.11.24
30.11.24